Kalaris Therapeutics CFO Resigns; Chief Accounting Officer Assumes Principal Financial Officer Role
KLRS has more than doubled off its 52-week low of $2.14.
Summary
Kalaris Therapeutics announced the resignation of its Chief Financial Officer, Matthew Gall, effective April 14, 2026, with Chief Accounting Officer Brett Hagen stepping in as Principal Financial Officer.
Key Events · Executive and Board Changes · KLRS
-
Chief Financial Officer Resigns
Matthew Gall notified Kalaris Therapeutics, Inc. of his decision to resign as Chief Financial Officer, effective April 14, 2026.
-
Chief Accounting Officer Appointed Principal Financial Officer
Brett Hagen, the Company's Chief Accounting Officer and principal accounting officer, will also serve as the principal financial officer, effective April 14, 2026.
Analysis · KLRS · Life Sciences
The departure of a Chief Financial Officer is a significant executive change that can raise questions about leadership stability and financial strategy. This event occurs shortly after Kalaris Therapeutics filed universal shelf and resale registration statements, signaling potential future capital raises. While the internal appointment of the Chief Accounting Officer as Principal Financial Officer provides immediate continuity, investors may scrutinize the reasons behind the CFO's resignation and its potential impact on the company's financial operations and ongoing capital raising efforts.
At the time of this filing, KLRS was trading at $6.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.1M. The 52-week trading range was $2.14 to $11.88. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.